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A bioavailability and pharmacokinetics study of
doxycycline was carried out on 30 healthy ostriches after a
single intravenous (IV), intramuscular (IM) and oral dose
of 15 mg/kg body weight. The plasma doxycycline
concentration was determined by HPLC/UV at 0
(pretreatment), 0.08, 0.25, 0.5 1, 2, 4, 6, 8, 12, 24 and 48 h
after administration. The plasma concentration-time
curves were examined using non-compartmental methods
based on the statistical moment theory for only the higher
dose. After IV administration, the elimination half-life
(t1/2β), mean residence time (MRT), volume of distribution
at the steady-state (Vss), volume of distribution (Vdarea) and
total body clearance (ClB) were 7.67 ± 0.62 h, 6.68 ± 0.86 h,
0.86 ± 0.16 l/kg, 1.67 ± 0.52 l/kg and 2.51 ± 0.63 ml/min/kg,
respectively. After IM and oral dosing, the mean peak
plasma concentrations (Cmax) were 1.34 ± 0.33 and 0.30 ±
0.04 µg/ml, respectively, which were achieved at a post-
administration time (tmax) of 0.75 ± 0.18, 3.03 ± 0.48 h,
respectively. The t1/2β, Vdarea and ClB after IM administration
were 25.02 ± 3.98 h, 23.99 ± 3.4 l/kg and 12.14 ± 1.71 ml/
min/kg, respectively and 19.25 ± 2.53 h, 61.49 ± 7 l/kg and
40.19 ± 3.79 ml/min/kg after oral administration, respectively.
The absolute bioavailability (F) of doxycycline was 5.03 and
17.52% after oral and IM administration, respectively.
These results show that the dose data from other animals
particularly mammals cannot be extrapolated to ostriches.
Therefore, based on these results along with those reported
in the literature, further studies on the pharmacokinetic/
pharmacodynamic, in vitro minimum inhibitory concentration
values and clinical applications of doxycycline in ostriches
are required.
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Introduction
Doxycycline is a semi-synthetic bacteriostatic tetracycline
and a broad-spectrum antibiotic against Gram-negative and
Gram-positive aerobic and anaerobic bacteria, Rickettsiae,
Chlamydiae, Mycoplasmas and some protozoa [25,32]. In
veterinary medicine, doxycycline is considered to be the
corner stone of the treatment for respiratory, urinary and
gastrointestinal tract diseases, on account of its pharmacological
and pharmacokinetics properties compared with other
antimicrobial agents [2,11].
The ostrich, Struthio camelus, is the largest living bird,
and has attracted considerable worldwide interest in
agriculture. Ostriches provide healthy red meat, excellent
quality hides, have reasonable feeding requirements and are
hardened to different environmental conditions [32]. However,
bacterial infections caused by E. coli, Mannheimia
haemolytica, Pseudomonas aeruginosa, Staphylococcus
aureus, Streptococcus viridans, Corynebacterium pyogenes ,
Chlamydia psittaci, Salmonellae, Colistridium , Proteus,
Heamophilus  and  Mycoplasma species  are frequently
isolated from ostriches suffering from enteric and respiratory
diseases [30]. This can lead to high mortality, particularly in
younger ostriches. There is a lack of information on the
pharmacokinetics/pharmacodynamics of various drugs in
ostriches. Hence, the use of drugs in ostriches including the
dosage regimen is based on the data obtained from other
animal species [16]. The disposition kinetics of doxycycline
has been examined in chicken [3], turkey [29], goat [17,23],
calve [20] and pig [5,25] but not in ostriches. Therefore, this
study examined the pharmacokinetics and bioavailability of
doxycycline in domestic ostriches after a single intravenous
(IV), intramuscular (IM) and oral dose.
Materials and Methods
Drugs
The working standard powder of doxycycline hydrochloride
(hyclate) was obtained from the Arab Pesticide and
Veterinary Drug Mfg. (AL-Ramtha, Jordan). The drug was
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dissolved in water to a final concentration of 150 mg/ml
prior to administration.
Experimental animals
Thirty healthy ostriches (Struthio camelus), 10-12 months
old and weighing 70-90 kg, were used in this study. The
ostriches were obtained from a local farm (Albekerat Ostrich
Ranch; Amman, Jordan). The animals were monitored for 2
weeks to determine if there were any apparent clinical signs
before administering the drug. The animals were housed in
an isolated open system pen. The ostriches were given
access to water and antibacterial-free food ad libitum.
Experimental design
In a preliminary study, 12 ostriches were divided into
three equal groups (4 ostriches/group) in a parallel design.
The ostriches in groups 1 to 3 were administered doxycycline
(5 mg/kg body weight) IV, IM and orally, respectively. This
dose was chosen based on the approved daily dose for goats
and sheep [2]. Doxycycline was administered in the right
brachial vein and iliotrochanteric muscle for IV and IM
administration, respectively, and was given orally through
a stomach tube. Food was withheld for 12 h before
administering the drug and was given 6 h after. However,
the peak level (Cmax) at the dose rate of 5 mg/kg was about
one third of other species (1.6 in goat versus 0.5 µg/ml in
ostrich) and hence the second dose rate was tripled [2]. In
the second trial, doxycycline was given to 30 ostriches at a
dose of 15 mg/kg body weight, which had been divided into
three equal groups (10 ostriches/group) in a parallel design.
The above-mentioned experimental protocol was followed
for this trial. A washout period of 14 days was used to
ensure complete clearance of the drug from ostriches used in
the first trial.
Sample collection
The blood samples (2-3 ml) were collected from the left
brachial and cutaneous ulnar veins into heparinized tubes at
0 (pretreatment), 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 and 48 h
after administering the drug. The samples were centrifuged
directly at ×1,000 g for 5 min. The plasma was then
harvested and stored at −20
oC until analysis.
Sample preparation
The plasma protein was precipitated by adding 300 µl
perchloric acid (16%) to 200 ml of ostrich plasma or a
standard sample. The mixture was vortexed for 30 s and
centrifuged for 5 min at ×1000 g. The clear supernatant was
injected directly into the high performance liquid chromatograph
(HPLC).
Drug analysis
The plasma concentrations of doxycycline were measured
by HPLC according to a slight modification of a previously
described method [1]. All the solvents used were of HPLC
grade; acetonitrile, methanol and water (Frutarom, UK), and
perchloric acid (ApliChem, Germany). The HPLC system
consisted of a pump (LC-10A DVP) with UV-vis detector
(SPD-10 AVP), auto injector (SIL-10A DVP), solvent
degasser (DGV-12 A) and Shimadzu class-VP software (Ver
6.12 SP4) (Shimadzu, Japan). Chromatographic separation
was performed using a Purospher Star RP-18e (5 µm, 125
mm ×4.6 mm) column (Merck, Germany) with an isocratic
mobile phase acetonitrile: methanol: 0.15% triflouroacetic
acid (23 : 25 : 52 v/v/v). The mobile phase was filtered
through a 0.45 µm membrane and degassed. The mobile
phase was eluted at a flow rate of 1.5 ml/min and detected at
a UV wavelength of 347 nm.
A standard calibration curve was prepared by adding
200 µl of doxycycline (1 mg/ml in water) to 800 µl of
antibacterial-free ostrich plasma. This was further diluted
into antibacterial-free ostrich plasma to produce solutions at
concentrations of 0.1, 0.5, 1, 5, 10, 50, 100 and 200 µg/ml.
The peak areas were achieved by the measurement of peak
area ratios using integration peak program (Class-VP software;
Shimadzu, Japan). The HPLC method was validated by
assessing the linearity, accuracy, precision, recovery and
sensitivity. Two standard calibration curves with 8
doxycycline concentrations (0.1, 0.5, 1, 5, 10, 50, 100 and
200 µg/ml) and 6 replicates of the quality control samples
(2, 25 and 150 µg/ml) were prepared and analyzed daily for
3 consecutive days. The calibration curves were linear over
the range of 0.10-200 µg/ml. The correlation coefficients of
the calibration curves were > 0.9993. The calculated detection
limit in the ostrich plasma was 0.05 µg/ml based on a signal-
to-noise ratio of 3 : 1, whereas the limit of quantitation was
0.10 µg/ml based on a signal-to-noise ratio of 6 : 1. The
analytical recoveries of doxycycline, which were calculated
by comparing the peak area ratios for the plasma samples
and aqueous samples, ranged from 79.3 to 85.6%. The
precision of the inter- and intra-day assay coefficient of
variation ranged from 2.4 to 7.8% at concentrations of 2, 25
and 150 µg/ml. The accuracy of the inter- and intra-day
assay ranged from 98.1~103.7%.
Pharmacokinetic and statistical analysis
The pharmacokinetics analysis of the data was performed
using non-compartmental analysis based on the statistical
moment theory (SMT) according to the method described
by Gibaldi and Perrier [13], with the help of a computerized
TopFit program [31]. The calculated parameters were: area
under plasma concentration-time curve (AUC) using linear
trapezoid method; area under the first moment curve
(AUMC); mean residence time (MRT), where MRT =
AUMC/AUC; volume of distribution (Vd area), where Vdarea
= dose/AUC (β); total body clearance (ClB), where ClB =
dose/AUC; apparent volume of distribution at steady state
(Vss), where Vss=M R T× CLB; elimination rate (kel) wasPharmacokinetics and bioavailability of doxycycline in ostriches 329
determined by least-square regression analysis of terminal
log-linear portions of the plasma concentration-time profile
(kel = 2.303 × slop); elimination half-life (t1/2β), where t1/2β =
0.639/kel; the maximum concentration (Cmax) and the
corresponding peak time (tmax) were determined by
inspecting the individual drug plasma concentration-time
profiles. The absolute bioavailability (F) was calculated as
(AUCnon-IV/AUC IV) ×100.
Statistical analysis was used to evaluate the differences in
pharmacokinetics parameters between IV, IM and oral
routes. The obtained results were statistically analyzed using
student t-test. The differences were considered significant
when p < 0.05. All data are expressed as mean ± SE.
Results
In a preliminary study, doxycycline (5 mg/kg body weight)
was administered IV, IM and orally to the ostriches in group
1 to 3 (4 ostriches/group), respectively. This dose was based
on the approved daily dose for goat and cattle. Fig. 1 shows
the mean plasma concentrations- time profile of doxycycline.
The concentrations were below the quantifiable concentration
(0.1 µg/ml) after 24 h. After a single IV injection of
doxycycline at a dose of 5 mg/kg body weight, the mean
plasma doxycycline concentration was 29.53 ± 8.52 µg/ml 5
min after injection. After IM and oral administration, the
absorption of doxycycline in all ostriches was rapid and
measurable at the first sampling time (5 min). The peak
plasma concentration of 0.79 ± 0.27 and 0.34 ± 0.02 µg/ml
after IM and oral administration was reached at 1 ± 0.35 and
0.52 ± 0.19 h, respectively.
Table 1 and Fig. 2 show the mean plasma concentrations-
time profile of doxycycline (15 mg/kg body weight) after
IV, IM and oral administration. Table 2 gives the
pharmacokinetics parameters. After the single IM and oral
administration of doxycycline (15 mg/kg body weight), the
plasma drug concentration reached a peak (C max) of 1.35 ±
0.33 and 0.30 ± 0.04 µg/ml at 0.75 ± 0.18 and 3.03 ± 0.48 h,
respectively. The absolute bioavailability (F) was 5.03 and
17.52% after oral and IM administration, respectively.
Discussion
The ostrich industry has become economically important.
However, to our knowledge, there are no pharmacokinetics
reports that have described the mathematical disposition of
doxycycline in ostriches through different administration
routes. Therefore, clinicians have been obliged to use
empirical approaches based on extrapolated doses from
other animal species including mammals (sheep, goat and
cattle) [16]. This approach may lead less effectiveness,
bacterial resistance, as well as increased toxicity and drug
residues.
Fig. 1. Plasma concentration-time profile of doxycycline after a n
IV, IM and oral dose of 5 mg/kg body weight as determined by
HPLC. The values are mean ± SE (n = 4).
Fig. 2. Plasma concentration-time profile of doxycycline after a n
IV, IM and oral dose of 15 mg/kg body weight as determined by
HPLC. The values are mean ± SE (n = 10).
Table 1. Doxycyline plasma concentrations in ostriches after a






0.08 80.28 ± 18.01 0.59 ± 0.06 0.08 ± 0.01
0.25 39.78 ± 5.400 0.79 ± 0.09 0.16 ± 0.05
0.5 25.51 ± 2.990 1.17 ± 0.34 0.11 ± 0.02
1 17.61 ± 2.290 1.14 ± 0.35  0.18 ± 0.02
2 12.98 ± 1.600 0.94 ± 0.22 0.21 ± 0.02
4 6.88 ± 0.89 0.73 ± 0.13 0.28 ± 0.04
6 4.58 ± 0.83 0.64 ± 0.11  0.18 ± 0.02
8 3.70 ± 0.70 0.55 ± 0.07  0.18 ± 0.02
12 2.43 ± 0.60 0.42 ± 0.05 0.17 ± 0.02
24 0.82 ± 0.23 0.33 ± 0.03 00.1 ± 0.01
48 0.17 ± 0.02 0.16 ± 0.00 ND*
 *ND: not detected. Values are mean ± SE (n = 10).330 Ehab A. Abu-Basha et al.
In a preliminary study, the doxycycline plasma concentrations
were below the therapeutic concentrations after a single IM
and oral dose (5 mg/kg body weight). Therefore, this study
examined the pharmacokinetics of doxycycline at a single
dose level of 15 mg/kg body weight. The pharmacokinetics
of doxycycline (15 mg/kg body weight) after a single IV, IM
and oral dose was described adequately using a non-
compartmental method, which was based on the SMT. After
a single IV dose of doxycycline (15 mg/kg body weight),
the t1/2β (7.67 h) was similar to those reported in chickens
[3,18] and turkeys [29] but different from those reported in
goats [2,17] and calves [27]. The long t 1/2β in ostriches
suggests that doxycycline is slowly eliminated from the
body. The ClB (2.51 ml/min/kg) was low and different from
those reported in turkeys [29] and goats [2]. However, these
results are similar to those reported in calves [27] and pigs
[26]. The long t1/2β calculated in this study indicates a low
body clearance value. Doxycycline is highly lipophilic in
nature and expected to be distributed more in fatty tissues
[28]. The high Vdarea (1.67 l/kg) indicates the rapid distribution
of doxycycline in the body. These results are similar to those
reported for turkeys [29], pigs [5] and chickens [18]. Whereas,
it is lower than those reported in goats [2,17]. The high
Vdarea obtained in this study might due to the wide
distribution of the drug coupled with its storage in various
tissue depots.
Following a single IM dose, the t1/2β (25.02 h) was higher
than those reported in healthy East African dwarf goats [23],
pigs [25] and non-lactating Egyptian goats [2]. Nevertheless,
these results are lower from those reported in infected
African dwarf goats [23]. The long t 1/2β indicates slow drug
release and absorption from the injection site. The other
reasons are the drug formula, dosage and other concurrent
circumstances associated with the animal’s status. In
addition, interspecies variation should be considered. The
bioavailability (F) of doxycycline after IM administration
(17.52%) was lower than those reported in non-lactating
Egyptian goats (99.4%) [2]. This might be the result of
differences in the physiological and biochemical properties
between ostriches and other animal species [6,10].
The most useful PK parameters are the AUC 0-24, Cmax and
time (T) during which the concentrations exceed a defined
PD threshold [19]. On the other hand, the minimum
inhibitory concentration (MIC) is the most useful PD
parameter. Tetracycline drugs are classified as being
concentration-time dependent, where the efficacy is most
closely related to the time the plasma concentration exceeds
the MIC by 1-5 fold for 40-100% of the inter-dosing interval
and  ≥ 125 of the AUC/MIC [19]. However, these values
have not been validated for doxycycline. Doxycycline
reached a peak plasma concentration (C max) of 1.35 µg/ml at
0.75 h after the IM injection. These results are in agreement
with those reported for goats [2] and pigs [25] but lower
than those reported for healthy East African dwarf goats
[23]. The mean plasma concentration detected in ostrich
plasma after the IM administration of doxycycline (15 mg/
kg body weight) was higher than the MICs for Mycoplasma
gallisepticum  (0.2 µg/ml) [15], Mycoplasma Pneumoniae
(< 0.5 µg/ml) [33], Bacteroides fragilis (0.016-0.032) [ 21],
Staphylococcus  aureus (0.25 µg/ml) [8], Streptococcus
pneumoniae (< 0.4 µg/ml) [4], Streptococcus zooepidemicus
(< 1.0 µg/ml) [8], Chlamydia psittaci (0.05-0.2 µg/ml) [9]
and porcine bacterial respiratory tract pathogens (Pasteurella
multocida,  Bordetella bronchiseotica,  Actinobacillus
pleyropneumoniae and Mycoplasma hyopneumoniae)
(0.016-2 µg/ml ) [7,24]. However, the doxycycline plasma
concentration was lower than the MICs for E. coli (1-4 µg/
ml),  Pseudomonas  aeruginosa (> 64 µg/ml) [22]  and
Enterococcus fecalis (8-32 µg/ml) [14]. There are no reports
on the doxycycline MICs for susceptible microorganisms in
ostriches. Therefore, the MICs used for comparison were
obtained from other animal species.
Table 2. Pharmacokinetic parameters of doxycycline in ostriches after a single IV, IM and oral dose
Parameters Units IV IM Oral
t1/2β h 7.67 ± 0.62 25.02 ± 3.98 19.25 ± 2.53
MRT h 6.68 ± 0.86 34.41 ± 5.30 27.73 ± 3.48
Vdarea l/kg 1.67 ± 0.52 23.99 ± 3.40 61.49 ± 7.00
Vss l/kg 0.86 ± 0.16 - -
ClB ml/min/kg 2.51 ± 0.63 12.14 ± 1.71 40.19 ± 3.79
Cmax µg/ml 80.12 ± 17.96 01.35 ± 0.33 00.30 ± 0.04
tmax h 0.08 ± 0.00 00.75 ± 0.18 03.03 ± 0.48
AUC0-48 µg . h/ml 130.21 ± 17.6200 14.96 ± 1.9200 4.74 ± 0.44
AUC0-∞ µg . h/ml 134.09 ± 18.2200 23.49 ± 2.4500 6.74 ± 0.66
F % - 17.52 5.03
Abbreviations: AUC, area under plasma concentration-time curve; Cl B, total body clearance; C max, maximum plasma concentration; t max, time to peak
concentration; Vss, the volume of distribution at steady-state; Vd area, volume of distribution; MRT, mean residence time; t 1/2β, elimination half-life; F,
absolute bioavailability. Values are mean ± SE (n = 10).Pharmacokinetics and bioavailability of doxycycline in ostriches 331
After the oral administration of doxycycline at a dose of
15 mg/kg body weight, the t1/2β (19.25 h) was different from
those reported in pigs [5,25], chickens [15], horses [12], and
calves [20]. The Vdarea was higher and the ClB was lower
than those reported in pigs [5]. The bioavailability (F) of
doxycycline (5.03 %) was lower than those observed in pigs
[5], calves [20], chickens [15] and turkeys [29]. The
concentration curves obtained after oral administration
indicated a slow absorption rate with a C max of 0.30 µg/ml
being observed at 3.03 h. The Cmax gained in the study was
lower than those observed in pigs [5], calves [20], horses
[12] and chickens [18]. On the other hand, the resultant t max
achieved is longer than those reported previously. Anatomical
differences between the gastrointestinal tract of ostriches
and other animals might contribute to the slow or/and
incomplete absorption after oral administration [6]. The C max
achieved in this study was lower than the MICs for most
susceptible bacteria. Nevertheless, doxycycline can be used
orally for its local action to treat enteritis associated with
susceptible pathogens.
These results show that the dose data from other animals
particularly mammals cannot be extrapolated to ostriches.
Therefore, further research on a higher dose level,
pharmacokinetic/pharmacodynamic,  in vitro determination
of the MICs and clinical trials will be needed to optimize the
efficacy and safe use of doxycycline in ostriches.
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